Lin Shu-Fu, Lin Jen-Der, Hsueh Chuen, Chou Ting-Chao, Wong Richard J
Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
Oncotarget. 2017 Jul 8;8(40):67990-68000. doi: 10.18632/oncotarget.19092. eCollection 2017 Sep 15.
Many human cancers have altered cyclin-dependent kinase activity. Inhibition of cyclin-dependent kinases may arrest cell cycle progression and represents an important strategy in the treatment of malignancies. We evaluated the therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor, as a treatment for anaplastic thyroid cancer. Roniciclib inhibited anaplastic thyroid cancer cell proliferation in a dose-dependent manner. Roniciclib activated caspase-3 activity and induced apoptosis. Cell cycle progression was arrested in G2/M phase. , the growth of anaplastic thyroid cancer xenograft tumors was retarded by roniciclib treatment without evidence of toxicity. These data provide a rationale for further clinical evaluation using roniciclib in the treatment of patients with anaplastic thyroid cancer.
许多人类癌症都存在细胞周期蛋白依赖性激酶活性的改变。抑制细胞周期蛋白依赖性激酶可能会阻止细胞周期进程，这是治疗恶性肿瘤的一项重要策略。我们评估了细胞周期蛋白依赖性激酶抑制剂罗尼西利布作为间变性甲状腺癌治疗药物的疗效。罗尼西利布以剂量依赖性方式抑制间变性甲状腺癌细胞增殖。罗尼西利布激活了半胱天冬酶-3的活性并诱导细胞凋亡。细胞周期进程在G2/M期停滞。此外，罗尼西利布治疗可延缓间变性甲状腺癌异种移植肿瘤的生长，且无毒性迹象。这些数据为进一步使用罗尼西利布对间变性甲状腺癌患者进行临床评估提供了理论依据。
